US6982260B1
(en)
|
1999-11-22 |
2006-01-03 |
Warner-Lambert Company |
Quinazolines and their use for inhibiting cyclin-dependent kinase enzymes
|
US7235551B2
(en)
*
|
2000-03-02 |
2007-06-26 |
Smithkline Beecham Corporation |
1,5-disubstituted-3,4-dihydro-1h-pyrimido[4,5-d]pyrimidin-2-one compounds and their use in treating csbp/p38 kinase mediated diseases
|
KR100850812B1
(ko)
|
2000-10-23 |
2008-08-06 |
스미스클라인 비참 코포레이션 |
신규 화합물
|
KR20060111716A
(ko)
|
2002-01-22 |
2006-10-27 |
워너-램버트 캄파니 엘엘씨 |
2-(피리딘-2-일아미노)-피리도[2,3-d]피리미딘-7-온
|
EP1499320B1
(en)
|
2002-04-19 |
2007-08-22 |
Smithkline Beecham Corporation |
Novel compounds
|
ATE493987T1
(de)
|
2002-05-22 |
2011-01-15 |
Amgen Inc |
Aminopyrimidin-derivate zur verwendung als vanilloid-rezeptor-liganden zur behandlung von schmerzen
|
AR041191A1
(es)
|
2002-08-08 |
2005-05-04 |
Amgen Inc |
Ligandos del receptor vanilloide y su uso en tratamientos
|
NZ544609A
(en)
*
|
2003-07-11 |
2008-07-31 |
Warner Lambert Co |
Isethionate salt of 6-acetyl-8-cyclopentyl-5-methyl-2-(5-piperazin-1-yl-pyridin-2-ylamino)-8H-pyrido[2,3-d]pyrimidin-7-one
|
JP4884219B2
(ja)
*
|
2003-07-29 |
2012-02-29 |
ゼノン・ファーマシューティカルズ・インコーポレイテッド |
ピリジル誘導体および治療剤としてのその用途
|
ES2375134T3
(es)
|
2003-07-30 |
2012-02-27 |
Xenon Pharmaceuticals Inc. |
Derivados de piperazina y su uso como agentes terapéuticos.
|
ATE506953T1
(de)
*
|
2003-08-07 |
2011-05-15 |
Rigel Pharmaceuticals Inc |
2,4-pyrimidindiamin-verbindungen und verwendungen als antiproliferative mittel
|
JP2007533635A
(ja)
|
2003-09-30 |
2007-11-22 |
アムジエン・インコーポレーテツド |
バニロイド受容体リガンドおよび治療おけるこれらの使用
|
WO2005077938A1
(en)
|
2004-02-11 |
2005-08-25 |
Amgen Inc. |
Vanilloid receptor ligands and their use in treatments
|
MY139645A
(en)
|
2004-02-11 |
2009-10-30 |
Amgen Inc |
Vanilloid receptor ligands and their use in treatments
|
EP1740184A1
(en)
*
|
2004-03-30 |
2007-01-10 |
Pfizer Products Incorporated |
Combinations of signal transduction inhibitors
|
JP2007532669A
(ja)
*
|
2004-04-13 |
2007-11-15 |
イカジェン インコーポレイテッド |
カリウムイオンチャネル調節剤としての多環式ピリミジン
|
CA2579143A1
(en)
|
2004-09-13 |
2006-03-23 |
Amgen Inc. |
Vanilloid receptor ligands and their use in treatments
|
CA2580856A1
(en)
|
2004-09-20 |
2006-03-30 |
Xenon Pharmaceuticals Inc. |
Heterocyclic derivatives and their use as stearoyl-coa desaturase inhibitors
|
AU2005286793A1
(en)
|
2004-09-20 |
2006-03-30 |
Xenon Pharmaceuticals Inc. |
Heterocyclic derivatives for the treatment of diseases mediated by stearoyl-CoA desaturase enzymes
|
EP1799668A1
(en)
|
2004-09-20 |
2007-06-27 |
Xenon Pharmaceuticals Inc. |
Heterocyclic derivatives and their use as mediators of stearoyl-coa desaturase
|
TW200626138A
(en)
|
2004-09-20 |
2006-08-01 |
Xenon Pharmaceuticals Inc |
Heterocyclic derivatives and their use as therapeutic agents
|
AU2005286647A1
(en)
|
2004-09-20 |
2006-03-30 |
Xenon Pharmaceuticals Inc. |
Heterocyclic derivatives and their use as stearoyl-CoA desaturase inhibitors
|
TW200626155A
(en)
|
2004-09-20 |
2006-08-01 |
Xenon Pharmaceuticals Inc |
Heterocyclic derivatives and their use as therapeutic agents
|
BRPI0515482A
(pt)
|
2004-09-20 |
2008-07-22 |
Xenon Pharmaceuticals Inc |
derivados heterocìclicos e seus usos como agentes terapêuticos
|
AU2005299489A1
(en)
|
2004-10-22 |
2006-05-04 |
Amgen Inc. |
Substituted nitrogen-containing heterocycles as vanilloid receptor ligands and their uses as medicament
|
JP5118972B2
(ja)
|
2004-10-29 |
2013-01-16 |
テイボテク・フアーマシユーチカルズ |
Hiv阻害性二環式ピリミジン誘導体
|
AU2006205850A1
(en)
*
|
2005-01-14 |
2006-07-20 |
Janssen Pharmaceutica N.V. |
Pyrazolopyrimidines as cell cycle kinase inhibitors
|
EP1846408B1
(en)
|
2005-01-14 |
2013-03-20 |
Janssen Pharmaceutica NV |
5-membered annelated heterocyclic pyrimidines as kinase inhibitors
|
WO2006089311A1
(en)
|
2005-02-15 |
2006-08-24 |
Amgen Inc. |
Vanilloid receptor ligands and their use in treatments
|
US7479558B2
(en)
*
|
2005-03-25 |
2009-01-20 |
Glaxo Group Limited |
Process for preparing pyrido[2,3-d]pyrimidin-7-one and 3,4-dihydropyrimido[4,5-d]pyrimidin-2(1H)-one derivatives
|
PE20100737A1
(es)
|
2005-03-25 |
2010-11-27 |
Glaxo Group Ltd |
Nuevos compuestos
|
PE20061193A1
(es)
*
|
2005-03-25 |
2006-12-02 |
Glaxo Group Ltd |
DERIVADOS DE 3,4-DIHIDROPIRIMIDO[4,5-d]PIRIMIDIN-2-[1H]-0NA COMO INHIBIDORES DE QUINASA p38
|
JP2008535822A
(ja)
*
|
2005-03-25 |
2008-09-04 |
グラクソ グループ リミテッド |
新規化合物
|
CA2618646A1
(en)
|
2005-06-03 |
2007-11-15 |
Xenon Pharmaceuticals Inc. |
Aminothiazole derivatives as human stearoyl-coa desaturase inhibitors
|
GB0512844D0
(en)
*
|
2005-06-23 |
2005-08-03 |
Novartis Ag |
Organic compounds
|
DE602007009508D1
(de)
*
|
2006-03-30 |
2010-11-11 |
Little Island Co Cork |
Hiv-inhibierende 5-(hydroxymethylen- und aminomethylen) substituierte pyrimidine
|
AR060358A1
(es)
|
2006-04-06 |
2008-06-11 |
Novartis Vaccines & Diagnostic |
Quinazolinas para la inhibicion de pdk 1
|
PE20080695A1
(es)
*
|
2006-04-27 |
2008-06-28 |
Banyu Pharma Co Ltd |
Derivados de dihidropirazolopirimidinona como inhibidores de quinasa weel
|
WO2007125405A2
(en)
*
|
2006-05-01 |
2007-11-08 |
Pfizer Products Inc. |
Substituted 2-amino-fused heterocyclic compounds
|
EP2441757A1
(en)
*
|
2006-07-31 |
2012-04-18 |
Praecis Pharmaceuticals Incorporated |
Aurora kinase inhibitors from an encoded small molecule library
|
WO2008016675A1
(en)
|
2006-08-01 |
2008-02-07 |
Praecis Pharmaceuticals Incorporated |
P38 kinase inhibitors
|
WO2008051493A2
(en)
|
2006-10-19 |
2008-05-02 |
Signal Pharmaceuticals, Llc |
Heteroaryl compounds, compositions thereof, and their use as protein kinase inhibitors
|
JPWO2008081928A1
(ja)
*
|
2006-12-28 |
2010-04-30 |
大正製薬株式会社 |
ピラゾロピリミジン化合物
|
GB0706632D0
(en)
*
|
2007-04-04 |
2007-05-16 |
Cyclacel Ltd |
New purine derivatives
|
JP2010525047A
(ja)
*
|
2007-04-27 |
2010-07-22 |
アストラゼネカ アクチボラグ |
増殖状態の処置のためのEphB4キナーゼ阻害剤としてのN’−(フェニル)−N−(モルホリン−4−イル−ピリジン−2−イル)−ピリミジン−2,4−ジアミン誘導体
|
EP2164841A1
(en)
|
2007-06-08 |
2010-03-24 |
Bayer CropScience SA |
Fungicide heterocyclyl-pyrimidinyl-amino derivatives
|
US8461147B2
(en)
*
|
2007-12-03 |
2013-06-11 |
Boehringer Ingelheim International Gmbh |
Diaminopyridines for the treatment of diseases which are characterised by excessive or anomal cell proliferation
|
AU2008343932B2
(en)
|
2007-12-19 |
2013-08-15 |
Amgen Inc. |
Fused pyridine, pyrimidine and triazine compounds as cell cycle inhibitors
|
AU2009233951B2
(en)
|
2008-04-07 |
2014-02-27 |
Amgen Inc. |
Gem-disubstituted and spirocyclic amino pyridines/pyrimidines as cell cycle inhibitors
|
RU2545023C9
(ru)
|
2008-06-10 |
2016-06-20 |
Эббви Инк. |
Трициклические соединения, содержащая их фармацевтическая композиция и их применение для лечения иммунологических и онкологических состояний
|
GB0812969D0
(en)
|
2008-07-15 |
2008-08-20 |
Sentinel Oncology Ltd |
Pharmaceutical compounds
|
EP2331547B1
(en)
*
|
2008-08-22 |
2014-07-30 |
Novartis AG |
Pyrrolopyrimidine compounds as cdk inhibitors
|
US8110578B2
(en)
|
2008-10-27 |
2012-02-07 |
Signal Pharmaceuticals, Llc |
Pyrazino[2,3-b]pyrazine mTOR kinase inhibitors for oncology indications and diseases associated with the mTOR/PI3K/Akt pathway
|
MX2011005621A
(es)
*
|
2008-11-28 |
2011-06-20 |
Kowa Co |
Derivado de piridin-3-carboxiamida.
|
CA2748319A1
(en)
|
2008-12-29 |
2010-07-08 |
Fovea Pharmaceuticals |
Substituted quinazoline compounds of general formula (i) and uses thereof for treating disorders relating to tyrosine kinase dysregulation
|
US20120041195A1
(en)
|
2009-02-13 |
2012-02-16 |
Fovea Pharmaceuticals |
Heterocyclic compounds
|
WO2010114894A1
(en)
|
2009-03-31 |
2010-10-07 |
Arqule, Inc. |
Substituted heterocyclic compounds
|
AU2010248886A1
(en)
|
2009-05-13 |
2011-12-01 |
The University Of North Carolina At Chapel Hill |
Cyclin dependent kinase inhibitors and methods of use
|
CN102573486A
(zh)
*
|
2009-06-08 |
2012-07-11 |
加利福尼亚资本权益有限责任公司 |
三嗪衍生物及其治疗应用
|
US8586751B2
(en)
|
2009-06-12 |
2013-11-19 |
Bristol-Myers Squibb Company |
Nicotinamide compounds useful as kinase modulators
|
NZ599549A
(en)
|
2009-10-26 |
2013-11-29 |
Signal Pharm Llc |
Methods of synthesis and purification of heteroaryl compounds
|
KR101785257B1
(ko)
|
2009-12-01 |
2017-10-16 |
애브비 인코포레이티드 |
신규한 트리사이클릭 화합물
|
CN102711470A
(zh)
|
2009-12-01 |
2012-10-03 |
雅培制药有限公司 |
新的三环化合物
|
UY33227A
(es)
|
2010-02-19 |
2011-09-30 |
Novartis Ag |
Compuestos de pirrolopirimidina como inhibidores de la cdk4/6
|
GB201007286D0
(en)
|
2010-04-30 |
2010-06-16 |
Astex Therapeutics Ltd |
New compounds
|
WO2011156698A2
(en)
|
2010-06-11 |
2011-12-15 |
Abbott Laboratories |
NOVEL PYRAZOLO[3,4-d]PYRIMIDINE COMPOUNDS
|
AR081960A1
(es)
|
2010-06-22 |
2012-10-31 |
Fovea Pharmaceuticals Sa |
Compuestos heterociclicos, su preparacion y su aplicacion terapeutica
|
CN106008533B
(zh)
|
2010-10-25 |
2018-01-23 |
G1治疗公司 |
Cdk抑制剂
|
US8691830B2
(en)
|
2010-10-25 |
2014-04-08 |
G1 Therapeutics, Inc. |
CDK inhibitors
|
WO2012068381A2
(en)
|
2010-11-17 |
2012-05-24 |
The University Of North Carolina At Chapel Hill |
Protection of renal tissues from schema through inhibition of the proliferative kisses cdk4 and cdk6
|
GB201020179D0
(en)
|
2010-11-29 |
2011-01-12 |
Astex Therapeutics Ltd |
New compounds
|
MX2013006101A
(es)
*
|
2010-12-17 |
2013-07-02 |
Hoffmann La Roche |
Compuestos heterociclicos nitrogenados sustituidos fusionados en posicion 6,6 y usos de los mismos.
|
US8754114B2
(en)
|
2010-12-22 |
2014-06-17 |
Incyte Corporation |
Substituted imidazopyridazines and benzimidazoles as inhibitors of FGFR3
|
GB201104267D0
(en)
|
2011-03-14 |
2011-04-27 |
Cancer Rec Tech Ltd |
Pyrrolopyridineamino derivatives
|
CA2830516C
(en)
|
2011-03-23 |
2017-01-24 |
Amgen Inc. |
Fused tricyclic dual inhibitors of cdk 4/6 and flt3
|
JP6027095B2
(ja)
|
2011-04-22 |
2016-11-16 |
シグナル ファーマシューティカルズ,エルエルシー |
置換されたジアミノカルボキサミドおよびジアミノカルボニトリルピリミジン、その組成物、ならびに、それを用いた治療方法
|
CN103998036B
(zh)
|
2011-10-19 |
2017-05-31 |
西格诺药品有限公司 |
利用tor激酶抑制剂治疗癌症
|
GB201118656D0
(en)
|
2011-10-28 |
2011-12-07 |
Astex Therapeutics Ltd |
New compounds
|
GB201118652D0
(en)
|
2011-10-28 |
2011-12-07 |
Astex Therapeutics Ltd |
New compounds
|
GB201118675D0
(en)
|
2011-10-28 |
2011-12-14 |
Astex Therapeutics Ltd |
New compounds
|
GB201118654D0
(en)
|
2011-10-28 |
2011-12-07 |
Astex Therapeutics Ltd |
New compounds
|
PE20141696A1
(es)
|
2011-12-02 |
2014-11-08 |
Signal Pharm Llc |
Composiciones farmaceuticas de 7-(6-(2-hidroxipropan-2-il) piridin-3-il)-1-((trans)-4-metoxiciclohexil)-3,4-dihidropirazino[2,3-b] pirazin-2(1h)-ona, una forma solida del mismo y metodos de su uso
|
JP6096807B2
(ja)
|
2012-01-13 |
2017-03-15 |
ブリストル−マイヤーズ スクイブ カンパニーBristol−Myers Squibb Company |
キナーゼ阻害剤として有用なトリアゾリル置換されたピリジル化合物
|
EP2802579B1
(en)
*
|
2012-01-13 |
2016-04-13 |
Bristol-Myers Squibb Company |
Thiazolyl- or thiadiazolyl-substituted pyridyl compounds useful as kinase inhibitors
|
US9242975B2
(en)
|
2012-01-13 |
2016-01-26 |
Bristol-Myers Squibb Company |
Heterocyclic-substituted pyridyl compounds useful as kinase inhibitors
|
JP6114317B2
(ja)
|
2012-02-24 |
2017-04-12 |
シグナル ファーマシューティカルズ,エルエルシー |
Torキナーゼ阻害剤の組合せ療法を用いて、非小細胞肺がんを処置する方法
|
EP2831080B1
(en)
|
2012-03-29 |
2017-03-15 |
Francis Xavier Tavares |
Lactam kinase inhibitors
|
WO2013170671A1
(zh)
*
|
2012-05-14 |
2013-11-21 |
华东理工大学 |
蝶啶酮衍生物及其作为egfr、blk、flt3抑制剂的应用
|
GB201209613D0
(en)
|
2012-05-30 |
2012-07-11 |
Astex Therapeutics Ltd |
New compounds
|
GB201209609D0
(en)
|
2012-05-30 |
2012-07-11 |
Astex Therapeutics Ltd |
New compounds
|
IL289834B1
(en)
|
2012-06-13 |
2024-03-01 |
Incyte Holdings Corp |
Conversion of tricyclic compounds as FGFR inhibitors
|
US9388185B2
(en)
|
2012-08-10 |
2016-07-12 |
Incyte Holdings Corporation |
Substituted pyrrolo[2,3-b]pyrazines as FGFR inhibitors
|
GB201216018D0
(en)
|
2012-09-07 |
2012-10-24 |
Cancer Rec Tech Ltd |
Pharmacologically active compounds
|
GB201216017D0
(en)
|
2012-09-07 |
2012-10-24 |
Cancer Rec Tech Ltd |
Inhibitor compounds
|
JP2015532281A
(ja)
*
|
2012-09-26 |
2015-11-09 |
マンカインド コーポレイション |
複数キナーゼ経路阻害剤
|
AU2013203714B2
(en)
|
2012-10-18 |
2015-12-03 |
Signal Pharmaceuticals, Llc |
Inhibition of phosphorylation of PRAS40, GSK3-beta or P70S6K1 as a marker for TOR kinase inhibitory activity
|
ES2616812T3
(es)
|
2012-11-08 |
2017-06-14 |
Bristol-Myers Squibb Company |
Compuestos piridilo sustituidos con heterociclo bicíclico útiles como moduladores de quinasa
|
PE20150953A1
(es)
|
2012-11-08 |
2015-06-20 |
Bristol Myers Squibb Co |
Compuestos de piridilo sustituidos con heteroarilo utiles como moduladores de cinasa
|
WO2014089913A1
(zh)
*
|
2012-12-12 |
2014-06-19 |
山东亨利医药科技有限责任公司 |
作为酪氨酸激酶抑制剂的并环化合物
|
US9266892B2
(en)
|
2012-12-19 |
2016-02-23 |
Incyte Holdings Corporation |
Fused pyrazoles as FGFR inhibitors
|
NZ630467A
(en)
|
2013-01-16 |
2017-02-24 |
Signal Pharm Llc |
Substituted pyrrolopyrimidine compounds, compositions thereof, and methods of treatment therewith
|
HUE046653T2
(hu)
|
2013-03-15 |
2020-03-30 |
G1 Therapeutics Inc |
Normál sejtek tranziens védelme kemoterápia során
|
WO2014139145A1
(en)
*
|
2013-03-15 |
2014-09-18 |
Hutchison Medipharma Limited |
Novel pyrimidine and pyridine compounds and usage thereof
|
CN107417691B
(zh)
|
2013-03-15 |
2020-06-26 |
G1治疗公司 |
高效的抗赘生剂和抗增生剂
|
JP2016516815A
(ja)
|
2013-04-17 |
2016-06-09 |
シグナル ファーマシューティカルズ,エルエルシー |
1−エチル−7−(2−メチル−6−(1H−1,2,4−トリアゾール−3−イル)ピリジン−3−イル)−3,4−ジヒドロピラジノ[2,3−b]ピラジン−2(1H)−オンに関する医薬製剤、プロセス、固形形態、及び使用方法
|
BR112015026292B1
(pt)
|
2013-04-17 |
2022-04-12 |
Signal Pharmaceuticals, Llc |
Uso de 1-etil-7-(2-metil-6-(1h-1,2,4-triazol-3-il)piridin-3-il)-3,4-dihidropirazino [2,3-b]pirazin-2(1h)- ona e métodos in vitro
|
BR112015026297B1
(pt)
|
2013-04-17 |
2022-08-23 |
Signal Pharmaceuticals, Llc |
Uso de um inibidor da quinase tor e quinazolinona 5-substituída, composição farmacêutica que os compreende, e kit
|
AU2014254052B2
(en)
|
2013-04-17 |
2019-06-06 |
Signal Pharmaceuticals, Llc |
Treatment of cancer with dihydropyrazino-pyrazines
|
TW201521725A
(zh)
|
2013-04-17 |
2015-06-16 |
Signal Pharm Llc |
使用tor激酶抑制劑組合療法以治療癌症之方法
|
NZ631082A
(en)
|
2013-04-17 |
2017-06-30 |
Signal Pharm Llc |
Methods for treating cancer using tor kinase inhibitor combination therapy
|
SG10201708111YA
(en)
|
2013-04-17 |
2017-11-29 |
Signal Pharm Llc |
Combination therapy comprising a dihydropyrazino-pyrazine compound and an androgen receptor antagonist for treating prostate cancer
|
SI2986610T1
(en)
|
2013-04-19 |
2018-04-30 |
Incyte Holdings Corporation |
Bicyclic heterocycles as inhibitors of FGFR
|
GB201307577D0
(en)
|
2013-04-26 |
2013-06-12 |
Astex Therapeutics Ltd |
New compounds
|
CN109503591B
(zh)
|
2013-05-29 |
2022-03-01 |
西格诺药品有限公司 |
二氢吡嗪并吡嗪化合物的药物组合物、其固体形式和它们的用途
|
ES2812605T3
(es)
|
2013-12-20 |
2021-03-17 |
Signal Pharm Llc |
Compuestos de diaminopirimidilo sustituidos, composiciones de los mismos y procedimientos de tratamiento con ellos
|
TW201609693A
(zh)
|
2014-01-03 |
2016-03-16 |
必治妥美雅史谷比公司 |
雜芳基取代之菸鹼醯胺化合物
|
EP3099672A4
(en)
|
2014-01-31 |
2017-09-20 |
ONO Pharmaceutical Co., Ltd. |
Fused imidazole compounds
|
GB201403536D0
(en)
|
2014-02-28 |
2014-04-16 |
Cancer Rec Tech Ltd |
Inhibitor compounds
|
JO3512B1
(ar)
|
2014-03-26 |
2020-07-05 |
Astex Therapeutics Ltd |
مشتقات كينوكسالين مفيدة كمعدلات لإنزيم fgfr كيناز
|
MA55696A
(fr)
|
2014-03-26 |
2022-02-23 |
Astex Therapeutics Ltd |
Combinaisons
|
US10736900B2
(en)
|
2014-03-26 |
2020-08-11 |
Astex Therapeutics Ltd |
Combinations of an FGFR inhibitor and an IGF1R inhibitor
|
JP2017514806A
(ja)
|
2014-04-16 |
2017-06-08 |
シグナル ファーマシューティカルズ,エルエルシー |
Torキナーゼ阻害剤組み合わせ療法を使用して癌を治療する方法
|
US9512129B2
(en)
|
2014-04-16 |
2016-12-06 |
Signal Pharmaceuticals, Llc |
Solid forms comprising 1-ethyl-7-(2-methyl-6-(1H-1,2,4-triazol-3-yl)pyridin-3-yl)-3,4-dihydropyrazino[2,3-b]pyrazin-2(1H)-one and a coformer
|
WO2015160882A1
(en)
|
2014-04-16 |
2015-10-22 |
Signal Pharmaceuticals, Llc |
SOLID FORMS COMPRISING 7-(6-(2-HYDROXYPROPAN-2YL) PYRIDIN-3-YL)-1-(TRANS)-4-METHOXYCYCLOHEXYL)-3, 4-DIHYDROPYRAZINO[2,3-b] PYRAZIN-2(1H)-ONE, AND A COFORMER, COMPOSITIONS AND METHODS OF USE THEREOF
|
NZ714742A
(en)
|
2014-04-16 |
2017-04-28 |
Signal Pharm Llc |
Solid forms of 1-ethyl-7-(2-methyl-6-(1h-1,2,4-triazol-3-yl)pyridin-3-yl)-3,4-dihydropyrazino[2,3-b]pyrazin-2(1h)-one, compositions thereof and methods of their use
|
WO2015161287A1
(en)
|
2014-04-17 |
2015-10-22 |
G1 Therapeutics, Inc. |
Tricyclic lactams for use in the protection of normal cells during chemotherapy
|
US9623028B2
(en)
|
2014-07-14 |
2017-04-18 |
Signal Pharmaceuticals, Llc |
Methods of treating a cancer using substituted pyrrolopyrimidine compounds, compositions thereof
|
NZ629796A
(en)
|
2014-07-14 |
2015-12-24 |
Signal Pharm Llc |
Amorphous form of 4-((4-(cyclopentyloxy)-5-(2-methylbenzo[d]oxazol-6-yl)-7h-pyrrolo[2,3-d]pyrimidin-2-yl)amino)-3-methoxy-n-methylbenzamide, compositions thereof and methods of their use
|
WO2016015597A1
(en)
|
2014-07-26 |
2016-02-04 |
Sunshine Lake Pharma Co., Ltd. |
Compounds as cdk small-molecule inhibitors and uses thereof
|
WO2016040858A1
(en)
|
2014-09-12 |
2016-03-17 |
G1 Therapeutics, Inc. |
Combinations and dosing regimes to treat rb-positive tumors
|
WO2016040848A1
(en)
|
2014-09-12 |
2016-03-17 |
G1 Therapeutics, Inc. |
Treatment of rb-negative tumors using topoisomerase inhibitors in combination with cyclin dependent kinase 4/6 inhibitors
|
US10851105B2
(en)
|
2014-10-22 |
2020-12-01 |
Incyte Corporation |
Bicyclic heterocycles as FGFR4 inhibitors
|
CN105622638B
(zh)
*
|
2014-10-29 |
2018-10-02 |
广州必贝特医药技术有限公司 |
嘧啶或吡啶并吡啶酮类化合物及其制备方法和应用
|
CN104496983B
(zh)
|
2014-11-26 |
2016-06-08 |
苏州明锐医药科技有限公司 |
一种帕博西尼的制备方法
|
CN104447743B
(zh)
*
|
2014-11-26 |
2016-03-02 |
苏州明锐医药科技有限公司 |
帕博西尼的制备方法
|
JOP20200201A1
(ar)
|
2015-02-10 |
2017-06-16 |
Astex Therapeutics Ltd |
تركيبات صيدلانية تشتمل على n-(3.5- ثنائي ميثوكسي فينيل)-n'-(1-ميثيل إيثيل)-n-[3-(ميثيل-1h-بيرازول-4-يل) كينوكسالين-6-يل]إيثان-1.2-ثنائي الأمين
|
MA41551A
(fr)
|
2015-02-20 |
2017-12-26 |
Incyte Corp |
Hétérocycles bicycliques utilisés en tant qu'inhibiteurs de fgfr4
|
ES2751669T3
(es)
|
2015-02-20 |
2020-04-01 |
Incyte Corp |
Heterociclos bicíclicos como inhibidores FGFR
|
US9580423B2
(en)
|
2015-02-20 |
2017-02-28 |
Incyte Corporation |
Bicyclic heterocycles as FGFR4 inhibitors
|
US10478494B2
(en)
|
2015-04-03 |
2019-11-19 |
Astex Therapeutics Ltd |
FGFR/PD-1 combination therapy for the treatment of cancer
|
CN106146515B
(zh)
|
2015-04-17 |
2020-09-04 |
常州隆赛医药科技有限公司 |
新型激酶抑制剂的制备及应用
|
EP3287463A4
(en)
*
|
2015-04-24 |
2018-07-11 |
Guangzhou Maxinovel Pharmaceuticals Co., Ltd. |
Condensed-ring pyrimidylamino derivative, preparation method therefor, and intermediate, pharmaceutical composition and applications thereof
|
CN106279173A
(zh)
*
|
2015-05-29 |
2017-01-04 |
华东理工大学 |
蝶啶酮衍生物作为egfr抑制剂的应用
|
US10202390B2
(en)
|
2015-06-24 |
2019-02-12 |
Bristol-Myers Squibb Company |
Heteroaryl substituted aminopyridine compounds
|
AR105112A1
(es)
|
2015-06-24 |
2017-09-06 |
Bristol Myers Squibb Co |
Compuestos de aminopiridina sustituida con heteroarilo
|
EP3313840B1
(en)
|
2015-06-24 |
2019-07-24 |
Bristol-Myers Squibb Company |
Heteroaryl substituted aminopyridine compounds
|
JP6805232B2
(ja)
|
2015-07-24 |
2020-12-23 |
セルジーン コーポレイション |
(1r,2r,5r)−5−アミノ−2−メチルシクロヘキサノール塩酸塩の合成方法及びそれに有用な中間体
|
HRP20220012T1
(hr)
|
2015-09-23 |
2022-04-01 |
Janssen Pharmaceutica Nv |
Bi-heteroaril supstituirani 1,4-benzodiazepini i njihova upotreba za liječenje raka
|
DK3353177T3
(da)
|
2015-09-23 |
2020-08-24 |
Janssen Pharmaceutica Nv |
Tricykliske heterocykler til behandling af cancer
|
US11365198B2
(en)
|
2015-10-16 |
2022-06-21 |
Abbvie Inc. |
Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-N-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof
|
US10550126B2
(en)
|
2015-10-16 |
2020-02-04 |
Abbvie Inc. |
Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-A]pyrrolo[2,3-e]-pyrazin-8-yl)-N-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof
|
US11773106B2
(en)
|
2015-10-16 |
2023-10-03 |
Abbvie Inc. |
Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-N-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof
|
US11524964B2
(en)
|
2015-10-16 |
2022-12-13 |
Abbvie Inc. |
Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-n-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof
|
SG10201913997WA
(en)
|
2015-10-16 |
2020-03-30 |
Abbvie Inc |
PROCESSES FOR THE PREPARATION OF (3S,4R)-3-ETHYL-4-(3H-IMIDAZO[1,2-a]PYRROLO[2,3-e]-PYRAZIN-8-YL)-N-(2,2,2-TRIFLUOROETHYL)PYRROLIDINE-1-CARBOXAMIDE AND SOLID STATE FORMS THEREOF
|
US11512092B2
(en)
|
2015-10-16 |
2022-11-29 |
Abbvie Inc. |
Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-n-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof
|
WO2018005863A1
(en)
|
2016-07-01 |
2018-01-04 |
G1 Therapeutics, Inc. |
Pyrimidine-based compounds for the treatment of cancer
|
KR102445288B1
(ko)
*
|
2016-07-01 |
2022-09-19 |
쥐원 쎄라퓨틱스, 인크. |
N-(헤테로아릴)-피롤로[3,2-d]피리미딘-2-아민의 합성
|
WO2018005860A1
(en)
*
|
2016-07-01 |
2018-01-04 |
G1 Therapeutics, Inc. |
Pyrimidine-based antiproliferative agents
|
CN109996800B
(zh)
*
|
2016-11-28 |
2021-11-19 |
帝人制药株式会社 |
吡啶并[3,4-d]嘧啶衍生物或其溶剂合物的晶体
|
WO2018129387A1
(en)
|
2017-01-06 |
2018-07-12 |
G1 Therapeutics, Inc. |
Combination therapy for the treatment of cancer
|
EA039189B1
(ru)
|
2017-05-11 |
2021-12-15 |
Бристол-Маерс Сквибб Компани |
Тиенопиридины и бензотиофены в качестве ингибиторов irak4
|
AR111960A1
(es)
|
2017-05-26 |
2019-09-04 |
Incyte Corp |
Formas cristalinas de un inhibidor de fgfr y procesos para su preparación
|
GB201709840D0
(en)
|
2017-06-20 |
2017-08-02 |
Inst Of Cancer Research: Royal Cancer Hospital |
Methods and medical uses
|
MX2019015731A
(es)
|
2017-06-22 |
2020-08-03 |
Celgene Corp |
Tratamiento de carcinoma hepatocelular caracterizado por infeccion por virus de hepatitis b.
|
BR112019027967A2
(pt)
|
2017-06-29 |
2020-07-14 |
G1 Therapeutics, Inc. |
forma b cristalina isolada, composição farmacêutica, método para o tratamento de um distúrbio, método de um composto ou composição, e, processo para produzir forma b cristalina.
|
CN107759596A
(zh)
*
|
2017-12-05 |
2018-03-06 |
安庆奇创药业有限公司 |
一种合成帕博西尼的方法
|
CN108299312B
(zh)
*
|
2018-03-29 |
2020-10-30 |
郑州大学第一附属医院 |
一组嘧啶类衍生物及其在制备抗肿瘤药物中的应用
|
EP3788047A2
(en)
|
2018-05-04 |
2021-03-10 |
Incyte Corporation |
Solid forms of an fgfr inhibitor and processes for preparing the same
|
MX2020011639A
(es)
|
2018-05-04 |
2021-02-15 |
Incyte Corp |
Sales de un inhibidor de receptores de factor de crecimiento de fibroblastos (fgfr).
|
WO2020041770A1
(en)
|
2018-08-24 |
2020-02-27 |
G1 Therapeutics, Inc. |
Improved synthesis of 1,4-diazaspiro[5.5]undecan-3-one
|
US11628162B2
(en)
|
2019-03-08 |
2023-04-18 |
Incyte Corporation |
Methods of treating cancer with an FGFR inhibitor
|
US11591329B2
(en)
|
2019-07-09 |
2023-02-28 |
Incyte Corporation |
Bicyclic heterocycles as FGFR inhibitors
|
WO2021062327A1
(en)
*
|
2019-09-27 |
2021-04-01 |
Jubilant Biosys Limited |
Fused pyrimidine compounds, compositions and medicinal applications thereof
|
BR112022007163A2
(pt)
|
2019-10-14 |
2022-08-23 |
Incyte Corp |
Heterociclos bicíclicos como inibidores de fgfr
|
WO2021076728A1
(en)
|
2019-10-16 |
2021-04-22 |
Incyte Corporation |
Bicyclic heterocycles as fgfr inhibitors
|
US11897891B2
(en)
|
2019-12-04 |
2024-02-13 |
Incyte Corporation |
Tricyclic heterocycles as FGFR inhibitors
|
KR20220131900A
(ko)
|
2019-12-04 |
2022-09-29 |
인사이트 코포레이션 |
Fgfr 억제제의 유도체
|
CN115551856A
(zh)
*
|
2020-02-28 |
2022-12-30 |
重庆复尚源创医药技术有限公司 |
作为cdk2/4/6抑制剂的化合物
|
WO2021219731A2
(en)
*
|
2020-04-28 |
2021-11-04 |
Iomx Therapeutics Ag |
Bicyclic kinase inhibitors and uses thereof
|
IL298294A
(en)
|
2020-05-19 |
2023-01-01 |
G1 Therapeutics Inc |
Cyclin-dependent kinase inhibitory compounds for the treatment of medical disorders
|
CN113801139A
(zh)
*
|
2020-06-12 |
2021-12-17 |
华东理工大学 |
作为rsk抑制剂的嘧啶并恶嗪衍生物及其应用
|
CN113801118A
(zh)
*
|
2020-06-12 |
2021-12-17 |
华东理工大学 |
作为rsk抑制剂的蝶啶酮衍生物及其应用
|
US10988479B1
(en)
|
2020-06-15 |
2021-04-27 |
G1 Therapeutics, Inc. |
Morphic forms of trilaciclib and methods of manufacture thereof
|
CN113087708A
(zh)
*
|
2021-04-06 |
2021-07-09 |
南方医科大学 |
一种蝶啶酮类化合物及其应用
|
EP4352059A1
(en)
|
2021-06-09 |
2024-04-17 |
Incyte Corporation |
Tricyclic heterocycles as fgfr inhibitors
|
TW202317105A
(zh)
|
2021-08-27 |
2023-05-01 |
南韓商柳韓洋行 |
作為egfr抑制劑之含六員雜芳基之胺基吡啶化合物
|
TW202317106A
(zh)
*
|
2021-08-27 |
2023-05-01 |
南韓商柳韓洋行 |
作為egfr抑制劑之取代胺基吡啶化合物
|
CN116514728A
(zh)
*
|
2022-01-28 |
2023-08-01 |
赛诺哈勃药业(成都)有限公司 |
一种喹唑啉衍生物及其用途
|
US20240092761A1
(en)
*
|
2022-07-18 |
2024-03-21 |
Iambic Therapeutics, Inc. |
Quinazoline compounds and methods of use
|